Skip to main content

Advertisement

Log in

Incidence of cancer among female patients with systemic lupus erythematosus in Korea

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

This study aims to ascertain the incidence of cancer in patients with systemic lupus erythematosus (SLE) in comparison with that in the general population in Korea, and to identify the cancer-types, the organ involvement, and the association with immunosuppressive therapy. The study subjects were consecutive SLE patients evaluated at Kangnam St. Mary’s hospital between 1997 and 2007. The incidence rate of cancer was calculated and was analyzed in comparison to that of age- and sex-matched cohort obtained from the Korea National Cancer Registry. Nine hundred fourteen patients were observed for a total of 5,716 person-years. A total of 16 cases of cancer occurred. The average age at the diagnosis of cancer and the mean disease duration were 43 years and 11 years, respectively. The standardized incidence ratio (SIR) of all cancers was 1.45 (95% CI 0.74–2.16); The SIRs for the three most frequent cancers were 3.42 for cervix cancer (CI 0.00–7.26), 15.37 for non-Hodgkin’s lymphoma (NHL; CI 2.90–37.68), and 43.55 for bladder cancer (CI 8.21–106.78). There were significant differences in the hematologic and renal involvement between SLE patients with cancer and without. Cyclophosphamide therapy, especially with cumulative dose more than 6 g (p = 0.017), seemed to contribute to the increased risk of cancer. Long disease duration, damage, and hematologic involvement were associated with increased risk of cancer occurrence. SLE patients are at high risk for NHL and bladder cancer. Active cancer screening is required in SLE patients with long disease duration and damage who are treated with high dose cyclophosphamide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Merrel M, Shulman LE (1995) Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J Chronic Dis 1:12–32

    Article  Google Scholar 

  2. Pistiner M, Wallace DJ, Nessim S et al (1991) Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 21:55–64

    Article  CAS  PubMed  Google Scholar 

  3. Cervera R, Khamashta MA, Font J et al (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestation in a cohort of 1,000 patients. Medicine 82:299–308

    Article  PubMed  Google Scholar 

  4. Gripenberg M, Helve T (1991) Outcome of systemic lupus erythematosus. A study of 66 patients over 7 years with reference to the predictive value of anti n-DNA antibody determination. Scand J Rheumatol 20:104–109

    Article  CAS  PubMed  Google Scholar 

  5. Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, Sarzi-Puttini P, Atzeni F, Piccoli A, Todesco S (2006) Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 119:700–706

    Article  PubMed  Google Scholar 

  6. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcón G, Senécal JL, Zummer M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley J, El-Gabalawy H, McCarthy T, St Pierre Y, Clarke A, Ramsey-Goldman R (2006) Mortality in systemic lupus erythematosus. Arthritis Rheum 54:2550–2557

    Article  CAS  PubMed  Google Scholar 

  7. Moss KE, Ioannou Y, Sultan SM, Haq I, Isenberg DA (2002) Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 61:409–413

    Article  CAS  PubMed  Google Scholar 

  8. Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR, Petri M, Edworthy S, Barr S, Gordon C, Bae SC, Sibley J, Isenberg D, Rahman A, Aranow C, Dooley MA, Steinsson K, Nived O, Sturfelt G, Alarcón G, Senécal JL, Zummer M, Hanly J, Ensworth S, Pope J, El-Gabalawy H, McCarthy T, St Pierre Y, Ramsey-Goldman R, Clarke A (2005) An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 52:1481–1490

    Article  CAS  PubMed  Google Scholar 

  9. Parikh-Patel A, White RH, Allen M, Cress R (2008) Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control 19:887–894

    Article  PubMed  Google Scholar 

  10. Cibere J, Sibley J, Haga M (2001) Systemic lupus erythematosus and the risk of malignancy. Lupus 10:394–400

    Article  CAS  PubMed  Google Scholar 

  11. Bjornadal L, Lofstrom B, Yin L, Lundberg I, Ekbom A (2002) Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 31:66–71

    Article  PubMed  Google Scholar 

  12. Pettersson T, Pukkala E, Teppo L, Friman C (1992) Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 51:437–439

    Article  CAS  PubMed  Google Scholar 

  13. Abu-Shakra M, Gladman DD, Urowitz MB (1996) Malignancy in systemic lupus erythematosus. Arthritis Rheum 39:1050–1054

    Article  CAS  PubMed  Google Scholar 

  14. Sultan SM, Ioannou Y, Isenberg DA (2000) Is there an association of malignancy with SLE? An analysis of 276 patients under long-term review. Rheumatology 39:1147–1152

    Article  CAS  PubMed  Google Scholar 

  15. Nived O, Bengtsson A, Jonsen A, Sturfelt G, Olsson H (2001) Malignancies during follow-up in an epidemiologically defined SLE inception cohort in southern Sweden. Lupus 10:500–504

    Article  CAS  PubMed  Google Scholar 

  16. Chun BC, Bae SC (2005) Mortality and cancer incidence in Korean patients with systemic lupus erythematosus: results from the Hanyang lupus cohort in Seoul, Korea. Lupus 14:635–638

    Article  PubMed  Google Scholar 

  17. Tarr T, Gyorfy B, Szekanecz E, Bhattoa HP, Zeher M, Szegedi G, Kiss E (2007) Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus: results from a single center. Ann N Y Acad Sci 1108:76–82

    Article  PubMed  Google Scholar 

  18. Ragnarsson O, Gröndal G, Steinsson K (2003) Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus. Lupus 12:687–691

    Article  CAS  PubMed  Google Scholar 

  19. Hochberg MC (1997) Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725

    Article  CAS  PubMed  Google Scholar 

  20. Isenberg DA, Gladman DD (2001) The systemic lupus international collaborating clinics group: origins and outcomes. Lupus 10:375–377

    Article  CAS  PubMed  Google Scholar 

  21. Incidence in Korea 1999–2001 (2005) Ministry of Health and Welfare, Republic of Korea

  22. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin P, Gordon C, Barr S, Edworthy S, Bae SC, Petri M, Sibley J, Isenberg D, Rahman A, Steinsson K, Aranow C, Dooley MA, Alarcon GS, Hanly J, Sturfelt G, Nived O, Pope J, Ensworth S, Rajan R, El-Gabalawy H, McCarthy T, St Pierre Y, Clarke A, Ramsey-Goldman R (2005) Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Rheum 53:781–784

    Article  CAS  PubMed  Google Scholar 

  23. Mellemkjer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH (1997) Non-Hodgkin’s lymphoma and other cancers among a cohort of patients with SLE. Arthritis Rheum 40:761–768

    Article  Google Scholar 

  24. Hansen A, Lipsky PE, Dörner T (2007) B-cell lymphoproliferation in chronic inflammatory rheumatic diseases. Nat Clin Pract Rheumatol 3:561–569

    Article  CAS  PubMed  Google Scholar 

  25. Youinou P et al (2006) B lymphocytes in the front line of autoimmunity. Autoimmun Rev 5:215–221

    Article  PubMed  Google Scholar 

  26. Lipsky PE (2001) Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2:764–766

    Article  CAS  PubMed  Google Scholar 

  27. Dörner T, Lipsky PE (2002) Abnormalities of B cell phenotype, immunoglobulin gene expression and the emergence of autoimmunity in Sjögren’s syndrome. Arthritis Res 4:360–371

    Article  PubMed  Google Scholar 

  28. Abu-Shakra M, Ehrenfeld M, Shoenfeld Y (2002) Systemic lupus erythematosus and cancer: associated or not? Lupus 11:137–144

    Article  CAS  PubMed  Google Scholar 

  29. Bernatsky S, Joseph L, Boivin JF, Gordon C, Urowitz M, Gladman D, Fortin PR, Ginzler E, Bae SC, Barr S, Edworthy S, Isenberg D, Rahman A, Petri M, Alarcón GS, Aranow C, Dooley MA, Rajan R, Sénécal JL, Zummer M, Manzi S, Ramsey-Goldman R, Clarke AE (2008) The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis 67:74–79

    Article  CAS  PubMed  Google Scholar 

  30. Chow SK, Looi LM, Loh CS, Yeap SS (2002) Cyclophosphamide-induced transitional cell carcinoma of bladder in lupus nephritis. Intern Med J 32:114–116

    Article  CAS  PubMed  Google Scholar 

  31. Ortiz A, Gonzalez-Parra E, Alvarez-Costa G, Egido J (1992) Bladder cancer after cyclophosphamide therapy for lupus nephritis. Nephron 60:378–379

    Article  CAS  PubMed  Google Scholar 

  32. Thrasher JB, Miller GJ, Wettlaufer JN (1990) Bladder leiomyosarcoma following cyclophosphamide therapy for lupus nephritis. J Urol 143:119–121

    CAS  PubMed  Google Scholar 

  33. Canoso JJ, Cohen AS (1974) Malignancy in a series of 70 patients with systemic lupus erythematosus. Arthritis Rheum 17:383–390

    Article  CAS  PubMed  Google Scholar 

  34. Ognenovski VM, Marder W, Somers EC, Johnston CM, Farrehi JG, Selvaggi SM, McCune WJ (2004) Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol 31:1763–1767

    CAS  PubMed  Google Scholar 

  35. Lopez Dupla M, Khamashta M, Pintado Garcia V, Lavilla Uriol P, Valencia Ortega E, Gil Aguado A (1993) Malignancy in systemic lupus erythematosus: a report of five cases in a series of 96 patients. Lupus 2:377–380

    Article  CAS  PubMed  Google Scholar 

  36. McCune WJ, Riskalla M (2002) Immunosuppressive drug therapy. In: Wace DJ, Hahn B (eds) Dubois’ lupus erythematosus, 6th edn. Linppincott Williams & Wilkins, Philadelphia, pp 1195–1217

    Google Scholar 

  37. Asten P, Barrett J, Symmons D (1999) Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 26:1705–1714

    CAS  PubMed  Google Scholar 

  38. Wells CK, Peduzzi PN, Feinstein AR (2001) Presenting manifestations, cigarette smoking, and detection bias in age at diagnosis of lung cancer. Ann Epidemiol 11:239–247

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

Thanks to Hyeon-Woo Yim (Department of Preventive Medicine, The Catholic University of Korea) and Seung Hee Jeong (CMC Clinical Research Coordinating Center, Department of Preventive Medicine, The Catholic University of Korea) for excellent analysis of this data.

This work was supported by the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korea Government (MEST; No. R11-2002-098-05003-0)

Disclosures

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sung-Hwan Park.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kang, K.Y., Kim, H.O., Yoon, H.S. et al. Incidence of cancer among female patients with systemic lupus erythematosus in Korea. Clin Rheumatol 29, 381–388 (2010). https://doi.org/10.1007/s10067-009-1332-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-009-1332-7

Keywords

Navigation